Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.39 |
| ▸ | WNT3A | P56704 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | DGKZ | Q13574 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15109020 | 0.86 | ALOX15 (0.36) | ENPP2KDM4ETDP1MMP3 | |
| SCHEMBL1465211 | 0.82 | ALOX15 (0.48) | ENPP2KIF11NPC1RAB9AKDM4E | |
| SCHEMBL1721735 | 0.79 | KIF11 (0.41) | ENPP2KIF11 | |
| SCHEMBL11155679 | 0.79 | CMA1 (0.33) | SLC6A4ENPP2PIK3CAPIK3CG | |
| SCHEMBL11157191 | 0.78 | ENPP2 (0.30) | ENPP2 | |
| SCHEMBL11157194 | 0.78 | ENPP2 (0.30) | ENPP2 | |
| SCHEMBL2537768 | 0.77 | CYP19A1 (0.43) | CTNNB1WNT3ACYP19A1FAAHSLC6A4 | |
| SCHEMBL10066096 | 0.76 | CYP19A1 (0.41) | CTNNB1WNT3ACYP19A1FAAHSLC6A4 | |
| SCHEMBL22657885 | 0.76 | FAAH (0.45) | CTNNB1WNT3ACYP19A1FAAHSLC6A4 | |
| SCHEMBL15151309 | 0.76 | CTNNB1 (0.41) | CTNNB1WNT3ACYP19A1FAAHSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1081 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107033120-B | Preparation method of 2- (2, 2-difluorobenzo [ D ] [1,3] dioxol-5-yl) acetonitrile | 苏州旺山旺水生物医药有限公司 | 2020-03-17 | — | — | CN | claimed |
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | SENSORIUM THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| CN-121922715-A | Novel nitrile electrolyte and application thereof in lithium metal battery | 中国科学院电工研究所 | 2026-04-24 | — | — | CN | disclosed |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2026-04-23 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-30 | — | — | US | disclosed |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-12350262-B2 | Methods of treatment for cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-08 | — | — | US | disclosed |
| EP-3880197-B9 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2007021982-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| EP-1716122-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060052358-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2006-03-09 | — | — | US | disclosed |
| WO-2005075435-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-08-18 | — | — | WO | disclosed |
| US-4405639-A | INSECTICIDES; PESTICIDES; MITICIDES; NEMATOCIDES; PARACITICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1983-09-20 | — | — | US | disclosed |
| US-4348323-A | FLUORINE-CONTAINING BENZODIOXINE INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1982-09-07 | — | — | US | disclosed |
| US-4284643-A | Combating arthropods with novel fluorine-containing phenylacetic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-18 | — | — | US | disclosed |
| EP-0008732-A2 | Fluorine-containing esters of phenylacetic acids, process for their preparation and their use as insecticides and acaricides; intermediate products for their preparation | BAYER AG (DE) | 1980-03-19 | — | — | EP | disclosed |
| US-4110345-A | 2,2-Difluoro-1,3-benzodioxole-5-(α-alkyl)-acetic acids, and their use for the preparation of insecticides and acaricides | AMERICAN CYANAMID COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-4105780-A | Insecticidal and acaricidal m-phenoxybenzyl esters of 2,2-difluoro-1,3-benzodioxole-5-(α-alkyl)acetic acids | AMERICAN CYANAMID COMPANY (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350262-B2 | Methods of treatment for cystic fibrosis | CFTR, SLC26A4, SCNN1B | CTNNB1 1642/4885WNT3A 1797/4885CYP19A1 4727/4885 |
| US-20260124173-A1 | THERAPEUTIC ALKALOID COMPOUNDS | ADRA1B, HTR1B, ADRB1 | CTNNB1 948/4885WNT3A 975/4885CYP19A1 688/4885 |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | CTNNB1 698/4885WNT3A 866/4885CYP19A1 4686/4885 |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, TMEM109 | CTNNB1 2290/4885WNT3A 1879/4885CYP19A1 2983/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | CTNNB1 1519/4885WNT3A 1201/4885CYP19A1 2005/4885 |
| US-20060052358-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"), such as N-(4,5-Diphenyl-thiazol-2-yl)-benzamide, used for treating genetic disorders; respiratory system disorders | CFTR, ABCC2, ABCC4 | CTNNB1 1285/4885WNT3A 2948/4885CYP19A1 4670/4885 |
| US-12508231-B2 | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | CFTR, MFAP1, CMA1 | CTNNB1 869/4885WNT3A 440/4885CYP19A1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.